Johnson & Johnson’s Actelion unit has agreed to pay the U.S. government more than $300 million to settle kickback allegations. The J&J division has been accused of at one point raising the price of its drug Tracleer “nearly 30 times the rate of overall inflation in the United States,” according to U.S. Attorney Andrew Lelling. (Endpoints)

U.S. healthcare spending increased by 3.9% to $3.5 trillion in 2017, making it the second year in a row that spending grew at a slower rate. A report from the U.S. Centers for Medicare and Medicaid Services found that hospital care, physician and clinical services, and prescription drugs contributed to the slower spending growth. (Reuters)

Apple Watch’s latest software update allows users to check for an irregular heart rhythm. The electrocardiogram app can notify users if there is consistent irregularity and when a users’ heart rate is low or high. Apple also released data from its clinical trial on Thursday. (CNBC)

Sandoz is planning to sell a generic version of EpiPen in early 2019. Prefilled syringes of the hormone epinephrine will be priced at two for $250 for adults. A version with a dosage for children will follow. Currently, EpiPen seller Mylan makes a generic version priced at $300 for two. (Associated Press)

Xeomin launched a campaign, Later Haters, to de-stigmatize anti-wrinkle injections. The campaign targets women in their 40s who want to “reclaim” their identity by using anti-aging injectables like Xeomin, a rival to Botox. (MM&M)